Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Change in Inventory: 2021-2025

Historic Change in Inventory for Apellis Pharmaceuticals (APLS) over the last 4 years, with Sep 2025 value amounting to -$5.4 million.

  • Apellis Pharmaceuticals' Change in Inventory rose 37.59% to -$5.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.4 million, marking a year-over-year decrease of 104.97%. This contributed to the annual value of $10.8 million for FY2024, which is 82.27% down from last year.
  • Apellis Pharmaceuticals' Change in Inventory amounted to -$5.4 million in Q3 2025, which was down 120.77% from $26.0 million recorded in Q2 2025.
  • In the past 5 years, Apellis Pharmaceuticals' Change in Inventory registered a high of $47.8 million during Q4 2023, and its lowest value of -$14.0 million during Q1 2025.
  • Its 3-year average for Change in Inventory is $7.1 million, with a median of -$144,000 in 2023.
  • In the last 5 years, Apellis Pharmaceuticals' Change in Inventory skyrocketed by 10,461.81% in 2024 and then crashed by 193.81% in 2025.
  • Over the past 5 years, Apellis Pharmaceuticals' Change in Inventory (Quarterly) stood at $14.6 million in 2021, then skyrocketed by 77.33% to $26.0 million in 2022, then skyrocketed by 84.18% to $47.8 million in 2023, then crashed by 120.96% to -$10.0 million in 2024, then skyrocketed by 37.59% to -$5.4 million in 2025.
  • Its Change in Inventory was -$5.4 million in Q3 2025, compared to $26.0 million in Q2 2025 and -$14.0 million in Q1 2025.